In April 2023, the FTC sent notices of penalty offenses to approximately 670 companies involved in marketing OTC drugs, homeopathic products, dietary supplements, and functional foods, putting them on notice that unsubstantiated claims could result in significant civil penalties.
The FTC's director of consumer protection stated at the time: "The requirement for advertisers to have adequate support for their advertising claims at the time they're made is a bedrock principle of FTC law."
What made those 670 notices noteworthy is not that the companies had no research. Many of them had studies. The problem was that the final claim went further than what the evidence demonstrated. That gap, between what the data proves and what the marketing says, is where claim substantiation failures most commonly originate.
This article provides a practical framework for matching claim language to evidence strength, identifying where the gap between research and marketing most commonly opens, and building a documentation process that makes every claim defensible.
The compliance risk in product claim development rarely comes from fabricating evidence. It comes from translating genuine evidence into language that implies more certainty, broader applicability, or stronger outcomes than the data supports.
Regulators evaluate the meaning of the final claim as a reasonable consumer would understand it, not just whether supporting research exists. The FTC's Health Products Compliance Guidance is explicit on this point: "FTC law focuses not on the marketer's intent, but on the consumer's understanding."
A claim that a legal team considers technically defensible may still violate FTC standards if a reasonable consumer would interpret it as promising something the evidence does not prove.
The distance between compliant and non-compliant claim language is often a single word. Three common word pairs where the compliance implications differ substantially:
The same study can support a "supports" claim or a "helps maintain" claim without supporting a "prevents" or "clinically proven" claim. Choosing the right word for the evidence level available is the core discipline of matching claims to evidence.
The steps below create a repeatable process for moving from research to defensible claim language. They apply to any product category where evidence-based claims are made: supplements, functional food and beverage, cosmetics, pharmaceuticals, and consumer health products.
Before drafting any claim language, define the specific and bounded finding from the research. This step requires resisting the instinct to start from the desired marketing message and instead starting from what the data actually shows.
For each piece of supporting evidence, document three things:
The claim can only be as broad as the conditions tested in the evidence. Writing this down before touching the marketing copy prevents the scope creep that generates substantiation gaps.
Every study has built-in limits that define the maximum scope of any claim derived from it. Understanding "claim boundaries" is central to product claim validation.
Ingredient claim vs finished product claim: If the research studied an isolated ingredient and the marketed product contains that ingredient in a different form, at a different dose, or in combination with other active ingredients, the ingredient study may not directly support a claim about the finished product's efficacy. Ingredient-level evidence supports ingredient-level claims: "Contains [ingredient], which has been studied for its role in X." It supports finished product claims only when the product delivers the ingredient at the studied dose and form.
Short-term vs long-term findings: A study conducted over four weeks produces evidence for a four-week effect. Claims that imply ongoing, sustained, or long-term benefit from a short-duration study extend beyond what was demonstrated.
Association vs causation: Observational and epidemiological research can establish associations but not causal relationships. A study showing that populations with higher intake of a nutrient have lower rates of a condition cannot directly support a causal product claim about that nutrient.
For additional context on how ingredient claims translate to label requirements, our guide on how to verify food ad ingredient claims effectively covers the practical application.
Once the scope of the evidence is defined, the language must be calibrated to reflect the confidence level accurately. The framework below provides a practical reference:
Strong evidence (multiple RCTs with consistent results, or a single large, well-designed RCT with a primary endpoint result):
Moderate evidence (single study, moderate sample size, or studies with mixed results):
Limited or indirect evidence (ingredient studies, mechanism research, or observational data):
The calibration test: if the available evidence is at the "moderate" level, only moderate-level language is appropriate. Using strong-evidence language for moderate evidence implies a certainty the research does not provide, which is the exact gap regulators identify in substantiation reviews.
Compliance is determined by how a reasonable consumer understands the claim, not how the legal team reads it. Step 4 requires evaluating the claim in its full context: the headline, the surrounding copy, the visuals, and the packaging design as a whole.
Several elements of packaging and advertising context can expand a claim's apparent scope without any change to the claim's text:
Ask these questions before approving the final packaging or ad:
For the intersection of packaging design and claim interpretation, our article on the role of labeling in marketing and how compliance meets brand identity covers how visual context shapes regulatory risk.
A claim that passes review today may need to be defended in a regulatory inquiry six months from now, or updated when a new study changes the evidence picture. A claim-to-evidence mapping document creates the institutional memory that makes both possible.
The document should include one record per claim, with these fields:
This record enables faster internal approvals for future claims built on the same evidence, supports efficient responses to regulatory inquiries, and ensures that claims stay synchronized with the evidence when formulations or evidence bases change.
Our broader guide on how to build science-backed product claims covers the full documentation workflow in more detail.
Understanding the most frequent substantiation failures helps teams identify where to apply closer scrutiny in their own review processes.
For teams in food and beverage categories where these patterns are particularly common, our overview of common food regulatory compliance mistakes in packaging covers how these mismatches lead to enforcement outcomes.
The strongest product claims are not the broadest ones. They are the ones that most precisely describe what the evidence demonstrates, in language calibrated to the confidence level the research supports.
The five-step framework above, defining what the evidence proves, identifying maximum claim scope, calibrating language to evidence strength, reviewing consumer interpretation, and documenting the claim-to-evidence mapping, creates the systematic approach that generates claims both marketing and regulatory teams can stand behind.
Brands that apply this framework before claims reach production spend less time revising after regulatory feedback, face fewer compliance challenges, and build consumer trust through claims that consistently deliver what they promise.
Upload your label artwork and claim copy to GetGenAI for an automated compliance review against FTC substantiation standards and current regulatory requirements.
How can a company determine if a claim is too broad for its supporting evidence?
Apply the scope test from Step 2: does the claim describe only what was directly measured, in the population that was studied, under the conditions tested? Any element of the claim that goes beyond those boundaries - a broader population, a longer time horizon, a stronger outcome - is potentially unsupported. A practical check: read the study's conclusion section and compare it to the claim wording. If the claim is stronger than what the study's own authors concluded, it is likely too broad.
Can the same clinical study support different claim strengths depending on wording?
Yes. A single study can support multiple claim tiers depending on how the finding is described. The primary endpoint result supports more direct benefit language. Secondary endpoint results support more qualified language. The ingredient as studied supports ingredient-level claims. The finished product, if it matches the study conditions, may support product-level claims. The same evidence base produces different maximum claim strengths at each tier, and choosing the right tier for each intended use is the core skill of claim substantiation.
What should brands do when a study supports a benefit but not the exact marketing claim they want?
Use the strongest language the evidence actually supports, and document why the specific desired wording would exceed that scope. If additional evidence is available that could support stronger language, commission or identify that research before making the stronger claim. If the evidence base cannot be expanded, the claim language must be adjusted to match what exists. Building a claim substantiation file that includes the rationale for claim wording decisions creates a clear record of good-faith compliance effort, which matters in the event of a regulatory inquiry.
Get intels on brand, platform, and regulatory changes, distilled by our compliance team
